• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

ChAdOx1 nCov-19 AstraZeneca COVID-19 vaccine not effective against B.1.351 variant

byCamille ZeitouniandHarsh Shah
April 30, 2021
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 variant. 

2. The ChAdOx1 nCov-19 vaccine was effective against mild-to-moderate non-variant COVID-19 infection after a single injection.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: With the emergence of COVID-19 variants, there is the need to investigate vaccine efficacy in this new context. In a randomized controlled trial from South Africa, researchers compared symptomatic COVID-19 infection rates after administration of the ChAdOx1 nCov-19 vaccine, manufactured by AstraZeneca. The study determined two doses of the vaccine were not effective at preventing mild-to-moderate COVID-19 infection caused by the B.1.351 variant. While no evidence was available for the vaccine’s efficacy against severe B.1.351 infection, this study suggests that second-generation COVID-19 vaccines may be needed to protect against this new variant. This study provides strong justification for using the ChAdOx1 nCov-19 vaccine in populations without the new B.1.351 variant. A major limitation of this study is its inability to establish the efficacy of the vaccine against severe covid-19 infection caused by the B.1.351 variant. Nonetheless, the findings were significant, as the study found that the vaccine is effective against non-variant covid-19 infection.

Click to read the study in the NEJM

Relevant Reading: Safety and efficacy of the ChAdOx1 nCov-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK.

In-Depth [randomized controlled trial]: This multicenter, double-blind, randomized controlled trial enrolled 2,026 patients between June 24 and November 9, 2020. Adults between the ages of 18 and 65 with no or well-managed prior comorbidities were eligible for participation in the trial. Patients with human immunodeficiency virus (HIV), previous COVID-19 infection, a history of anaphylaxis after vaccination, and obesity were excluded from the study. Patients were randomized in 1:1 ratio to receive either the ChAdOx1 nCovid-19 vaccine or placebo, respectively. The primary endpoint was symptomatic COVID-19 infection after two weeks following the second injection confirmed by PCR testing. The study also aimed to investigate the efficacy of the vaccine against the new B.1.351 variant. There were 42 cases of mild and moderate COVID-19 infection confirmed, of which 39 cases were caused by the B.1.351 variant. Vaccine recipients accounted for 19 (2.5%) of these infections, while placebo recipients made up the remaining 23 (3.2%) cases. The study revealed a 75.4% vaccine efficacy (95% confidence interval [CI], 8.7 to 95.5) for the prevention of mild-to-moderate COVID-19 infection caused by non-B.1.351 variant two weeks after just a single injection. However, vaccine efficacy against the B.1.351 variant was determined to be 10.4% (95% CI, -76.8 to 54.8). The study concluded that the ChAdOx1 nCovid-19 vaccine does not protect against mild-to-moderate COVID-19 infection caused by the B.1.351 variant. No conclusion was possible on vaccine prevention of severe COVID-19 infection caused by the B.1.351 variant.

RELATED REPORTS

COVID-19 vaccination and infection-acquired immunity provide protection against SARS-CoV-2 infection

Immune thrombocytopenia and thrombosis mortality predictors following SARS-CoV-2 vaccine

Third dose of ChAdOx1 nCoV-19 vaccine and prolonged second dose-intervals are both associated with increased antibody titers

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: astrazenecaB.1.351ChAdOx1 nCoV-19 vaccine
Previous Post

Sex-related disparities in cardiovascular health care among patients with premature atherosclerotic cardiovascular disease

Next Post

Sotatercept decreased vascular resistance in pulmonary arterial hypertension

RelatedReports

Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

COVID-19 vaccination and infection-acquired immunity provide protection against SARS-CoV-2 infection

March 2, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Cardiology

Immune thrombocytopenia and thrombosis mortality predictors following SARS-CoV-2 vaccine

November 10, 2021
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Third dose of ChAdOx1 nCoV-19 vaccine and prolonged second dose-intervals are both associated with increased antibody titers

September 21, 2021
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Heterologous ChAdOx1 prime-boosted vaccination schedules are non-inferior to homologous vaccination

September 15, 2021
Next Post
Selexipag may decrease mortality related to pulmonary arterial hypertension: The GRIPHON study

Sotatercept decreased vascular resistance in pulmonary arterial hypertension

Novel biodegradable sirolimus-eluting stents non-inferior to durable everolimus-eluting stents [BIOSCIENCE trial]

Tailored antiplatelet therapy improves outcomes in patients undergoing percutaneous coronary intervention

Isolated mild/moderate thrombocytopenia may not require intervention

Association of oral corticosteroid bursts with severe adverse events in children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
  • #VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.